The company described the move as an 'important milestone'.
Ranbaxy did its maiden public issue in 1973.
Hold your breath as Rediff.com brings to you some of the picturesque places that the cyclists race through at the Tour.
The 2nd major of the year, the French Open will start on the weekend. With the clay-court grand slam starting on Sunday, here is the list of French Open champions over the years
Zlatan Ibrahimovic has once again made the shortlist of for FIFA's goal of the year award, giving him a chance to retain the trophy he won last year.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Western drugmakers, including Pfizer Inc, Novartis AG, Roche Holding AG and Sanofi SA, covet a bigger share of the fast-growing Indian drugs market.
Welcome to India's medical devices companies which are successfully locking horns with global giants, whether in India or abroad.
Modi urged the Swiss business leaders to explore the investment opportunities in India.
The 30-somethings have enjoyed themselves at the French Open this year and American twins Bob and Mike Bryan continued the trend by winning a record-extending 14th Grand Slam doubles title at Roland Garros on Saturday.
Australia Davis Cup captain Pat Rafter named three teenagers in his squad on Tuesday for their away tie against France, their first World Group appearance since 2007.
For Chef Thomas Zacharias, Chef Floyd Cardoz, was a partner, mentor. And family.
Prithvi Shaw, Jason Sangha and Mujeeb Zadran are among the cricketers whose performances will be watched keenly in the upcoming ICC Under-19 Cricket World Cup.
The hotel is popular with westerners and United Nations staff and often used by French troops with Operation Barkhane, a force based in Chad and set up to combat Islamist militants across Africa's vast, arid Sahel region.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
List of men's singles champions at Wimbledon:
'India missed the software products revolution (and now is in danger of missing the platform revolution), complacent that we are the software experts of the world based on IT services prowess,' points out Rajeev Srinivasan.
10 things you need to know about the life of Liliane Bettencourt.
30 years later, relatives of the 329 people who perished in the Kanishka bombing gathered at a moving service in Ahakista, Cork in Ireland.
For the first time in India, Swiss Learning, an educational body managed by the Heads of Swiss Educational Institutes, has brought representatives from various schools from the country to meet stakeholders, Indian schools and parents of potential students.
The Sensex ended below 28,000 for the second straight day at 27,869.
The 67th annual Primetime Emmy Awards took place at the Microsoft Theater in Downtown Los Angeles, California, on September 20.
The yellowing obituaries are looking premature as serve-and-volley tennis creeps, with a few tweaks, towards a renaissance of sorts.
The drive against insider trading comes after SEBI last year received enhanced investigation powers from parliament, including the ability to monitor call records.
'Who would have thought that Brexit would take place or Donald Trump would become US president or Kim Jong-un's madness could bring the prospect of nuclear war over Asia?' 'It is the time of the unexpected; the French elections should perhaps be seen in this perspective,' says Claude Arpi.
Britain's Andy Murray won lifted his second Wimbledon title after defeating Canadian Milos Raonic 6-4 7-6(3) 7-6(2) on Sunday. Following that clinical performance, here is a list of Wimbledon men's singles champions since 1922....
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances